Literature DB >> 27868009

The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies.

Jennifer L Wilkinson-Berka1, Devy Deliyanti1.   

Abstract

Entities:  

Year:  2016        PMID: 27868009      PMCID: PMC5104608          DOI: 10.21037/atm.2016.10.27

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  20 in total

1.  Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A.

Authors:  Jean-Sébastien Joyal; Nicholas Sitaras; François Binet; Jose Carlos Rivera; Andreas Stahl; Karine Zaniolo; Zhuo Shao; Anna Polosa; Tang Zhu; David Hamel; Mikheil Djavari; Dario Kunik; Jean-Claude Honoré; Emilie Picard; Alexandra Zabeida; Daya R Varma; Gilles Hickson; Joseph Mancini; Michael Klagsbrun; Santiago Costantino; Christian Beauséjour; Pierre Lachapelle; Lois E H Smith; Sylvain Chemtob; Przemyslaw Sapieha
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

2.  From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.

Authors:  Ricardo J Giordano; Marina Cardó-Vila; Ahmad Salameh; Cristiane D Anobom; Benjamin D Zeitlin; David H Hawke; Ana P Valente; Fábio C L Almeida; Jacques E Nör; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-26       Impact factor: 11.205

3.  VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.

Authors:  Shay Soker; Hua-Quan Miao; Masashi Nomi; Seiji Takashima; Michael Klagsbrun
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

4.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Müller cell-derived VEGF is a significant contributor to retinal neovascularization.

Authors:  Yanyan Bai; Jian-xing Ma; Junjing Guo; Juanjuan Wang; Meili Zhu; Ying Chen; Yun-Zheng Le
Journal:  J Pathol       Date:  2009-12       Impact factor: 7.996

6.  Ten years of anti-vascular endothelial growth factor therapy.

Authors:  Napoleone Ferrara; Anthony P Adamis
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

Review 7.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

Authors:  Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong
Journal:  Lancet Glob Health       Date:  2014-01-03       Impact factor: 26.763

8.  The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis.

Authors:  Przemyslaw Sapieha; Mirna Sirinyan; David Hamel; Karine Zaniolo; Jean-Sébastien Joyal; Jang-Hyeon Cho; Jean-Claude Honoré; Elsa Kermorvant-Duchemin; Daya R Varma; Sophie Tremblay; Martin Leduc; Lenka Rihakova; Pierre Hardy; William H Klein; Xiuqian Mu; Orval Mamer; Pierre Lachapelle; Adriana Di Polo; Christian Beauséjour; Gregor Andelfinger; Grant Mitchell; Florian Sennlaub; Sylvain Chemtob
Journal:  Nat Med       Date:  2008-10-05       Impact factor: 53.440

Review 9.  Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.

Authors:  Tomas A Moreno; Stephen J Kim
Journal:  Semin Ophthalmol       Date:  2016-04-26       Impact factor: 1.975

Review 10.  Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.

Authors:  Shiqi Yang; Jingke Zhao; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2016-06-02       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.